FREELINE THERAPEUTICS HLDGS's ticker is FRLN and the CUSIP is 35655L107. A total of 20 filers reported holding FREELINE THERAPEUTICS HLDGS in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,217,990 | +64.3% | 1,466,507 | -0.0% | 9.26% | +62.4% |
| Q2 2023 | $3,783,591 | -62.6% | 1,466,508 | -93.3% | 5.70% | -65.3% |
| Q1 2023 | $10,118,905 | -3.2% | 21,997,620 | 0.0% | 16.45% | -0.8% |
| Q4 2022 | $10,451,069 | -31.6% | 21,997,620 | 0.0% | 16.59% | -37.5% |
| Q3 2022 | $15,282,000 | -20.8% | 21,997,620 | 0.0% | 26.56% | -3.2% |
| Q2 2022 | $19,307,000 | +230.5% | 21,997,620 | 0.0% | 27.43% | +391.6% |
| Q1 2022 | $5,841,000 | 0.0% | 21,997,620 | +645.7% | 5.58% | 0.0% |
| Q4 2021 | $5,841,000 | – | 2,950,000 | – | 5.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,466,507 | $6,217,990 | 9.26% |